^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    13h
    Cevostamab Following CAR T Cell Therapy for RRMM (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cevostamab (RG6160)
    13h
    EPCOR+LONCA: Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=26, Recruiting, University of Miami | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epkinly (epcoritamab-bysp) • Zynlonta (loncastuximab tesirine-lpyl)
    20h
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    surovatamig (AZD0486)
    1d
    A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=104, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    1d
    A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL (clinicaltrials.gov)
    P1/2, N=281, Recruiting, Amgen | Trial primary completion date: Jul 2027 --> Nov 2027
    Trial primary completion date • Minimal residual disease
    1d
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    2d
    A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia (clinicaltrials.gov)
    P1/2, N=158, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Trial completion date: Feb 2028 --> Sep 2031 | Trial primary completion date: Oct 2026 --> Sep 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    2d
    Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    3d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    3d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    Revuforj (revumenib)
    3d
    Tarlatamab for small-cell lung cancer. (PubMed, Expert Opin Biol Ther)
    Most data come from SCLC; in the other two diseases, tarlatamab is in early clinical development. Tarlatamab is an effective therapy mainly in relapsed/progressed SCLC, and its assessment in limited SCLC alone or combined with other therapies is supported by the existing data.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)